Cargando…
Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology ce...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600177/ https://www.ncbi.nlm.nih.gov/pubmed/23533811 http://dx.doi.org/10.1155/2013/672027 |
_version_ | 1782475598695759872 |
---|---|
author | Fusco, Vittorio Galassi, Claudia Berruti, Alfredo Ortega, Cinzia Ciuffreda, Libero Scoletta, Matteo Goia, Franco Migliario, Mario Baraldi, Anna Boccadoro, Mario Loidoris, Anastasios Bertetto, Oscar |
author_facet | Fusco, Vittorio Galassi, Claudia Berruti, Alfredo Ortega, Cinzia Ciuffreda, Libero Scoletta, Matteo Goia, Franco Migliario, Mario Baraldi, Anna Boccadoro, Mario Loidoris, Anastasios Bertetto, Oscar |
author_sort | Fusco, Vittorio |
collection | PubMed |
description | Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology centers of a regional network. Results. By December 2008, 221 cases were registered. We report details of 200 cases, identified after cross-checking reports from centres of medical oncology, haematology, and oral care. Primary neoplasm was breast cancer (39%), myeloma (32%), prostate cancer (16%), and other types of cancer (8%). In about 50% of the cases a history of dental extraction was present. Zoledronic acid was administered (alone or with other BP) to 178 patients (89%). Median time from first infusion to ONJ diagnosis was 21.0 (zoledronic acid only) and 39.0 months (pamidronate only). The number of ONJ cases per year was 3 in 2003, 21 in 2004, 58 in 2005, 60 in 2006, 37 in 2007, and 21 in 2008. Conclusion. The number of new ONJ cases in cancer and myeloma patients increased until 2006 and then reduced. The possible reasons of this trend (introduction of zoledronic acid; increase of ONJ awareness; diffusion of preventive dental measures; late modifications of BP prescription) are herein discussed. |
format | Online Article Text |
id | pubmed-3600177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36001772013-03-26 Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) Fusco, Vittorio Galassi, Claudia Berruti, Alfredo Ortega, Cinzia Ciuffreda, Libero Scoletta, Matteo Goia, Franco Migliario, Mario Baraldi, Anna Boccadoro, Mario Loidoris, Anastasios Bertetto, Oscar ISRN Oncol Clinical Study Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology centers of a regional network. Results. By December 2008, 221 cases were registered. We report details of 200 cases, identified after cross-checking reports from centres of medical oncology, haematology, and oral care. Primary neoplasm was breast cancer (39%), myeloma (32%), prostate cancer (16%), and other types of cancer (8%). In about 50% of the cases a history of dental extraction was present. Zoledronic acid was administered (alone or with other BP) to 178 patients (89%). Median time from first infusion to ONJ diagnosis was 21.0 (zoledronic acid only) and 39.0 months (pamidronate only). The number of ONJ cases per year was 3 in 2003, 21 in 2004, 58 in 2005, 60 in 2006, 37 in 2007, and 21 in 2008. Conclusion. The number of new ONJ cases in cancer and myeloma patients increased until 2006 and then reduced. The possible reasons of this trend (introduction of zoledronic acid; increase of ONJ awareness; diffusion of preventive dental measures; late modifications of BP prescription) are herein discussed. Hindawi Publishing Corporation 2013-02-27 /pmc/articles/PMC3600177/ /pubmed/23533811 http://dx.doi.org/10.1155/2013/672027 Text en Copyright © 2013 Vittorio Fusco et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Fusco, Vittorio Galassi, Claudia Berruti, Alfredo Ortega, Cinzia Ciuffreda, Libero Scoletta, Matteo Goia, Franco Migliario, Mario Baraldi, Anna Boccadoro, Mario Loidoris, Anastasios Bertetto, Oscar Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title | Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title_full | Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title_fullStr | Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title_full_unstemmed | Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title_short | Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) |
title_sort | decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-western italy) |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600177/ https://www.ncbi.nlm.nih.gov/pubmed/23533811 http://dx.doi.org/10.1155/2013/672027 |
work_keys_str_mv | AT fuscovittorio decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT galassiclaudia decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT berrutialfredo decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT ortegacinzia decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT ciuffredalibero decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT scolettamatteo decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT goiafranco decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT migliariomario decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT baraldianna decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT boccadoromario decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT loidorisanastasios decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly AT bertettooscar decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly |